Aminoglutethimide in the management of metastatic breast cancer

Niramol Savaraj, Michael B. Troner

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Aminoglutethimide with dexamethasone has been utilized in 26 patients with metastatic breast cancer who had prior response to hormonal manipulation and/or positive estrogen receptor. Objective tumor response (CR + PR) has been achieved in 13 of 26 patients. Responses were seen in soft tissue, bone, and pleura. Six of 26 patients had stable disease and 7 of 26 patients had progressive disease. The median duration of response is 12.8 months. The median survival for the responders has not been reached. Non-responding patients had a median survival of five months. Side effects were minimal, including mild lethargy, rash, fever, and weight gain. This regimen is well tolerated and can be used effectively in metastatic hormone-receptor-positive breast cancer.

Original languageEnglish (US)
Pages (from-to)251-263
Number of pages13
JournalMedical and Pediatric Oncology
Issue number3
StatePublished - 1980


  • Aminoglutethimide
  • Dexamethasone
  • breast cancer
  • cortisol
  • medical adrenalectomy

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research


Dive into the research topics of 'Aminoglutethimide in the management of metastatic breast cancer'. Together they form a unique fingerprint.

Cite this